Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

Oncogene volume 20, pages 3206–3216 (2001)Cite this article

Abstract

The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can efficiently stabilize and activate nuclear p53 in tumor cells with MDM2 amplification or cytoplasmic p53. These inhibitors block the degradation of p53 without affecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315. Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion. These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory effect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Addison C, Jenkin JR, Sturzbecher HW . 1990 Oncogene 5: 423–426

  • Andera L, Wasylyk B . 1997 Mol. Med. 3: 852–863

  • Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D . 1990 Proc. Natl. Acad. Sci. USA 87: 4766–4770

  • Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P . 1999 Oncogene 18: 1723–1732

  • Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, Hupp TR . 2000 Oncogene 19: 3829–3839

  • Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP . 1997 Curr. Biol. 7: 860–869

  • Chang D, Chen F, Zhang F, McKay BC, Ljungman M . 1999 Cell Growth. Differ. 10: 155–162

  • Chehab NH, Malikzay A, Appel M, Halazonetis TD . 2000 Genes. Dev. 14: 278–288

  • Chen J, Marechal V, Levine AJ . 1993 Mol. Cell Biol. 13: 4107–4114

  • Chen L, Agrawal S, Zhou W, Zhang R, Chen J . 1998 Proc. Natl. Acad. Sci. USA 95: 195–200

  • Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J . 1999 Mol. Med. 5: 19–32

  • Cordon Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ . 1994 Cancer Res. 54: 794–799

  • David-Pfeuty T, Chakrani F, Ory K, Nouvian-Dooghe Y . 1996 Cell Growth Differ. 7: 1211–1225

  • Gossen M, Bujard H . 1992 Proc. Natl. Acad. Sci. USA 89: 5547–5551

  • Hajduch M, Havlieek L, Vesely J, Novotny R, Mihal V, Strnad M . 1999 Adv. Exp. Med. Biol. 457: 341–353

  • Hall PA, McKee PH, Menage HD, Dover R, Lane DP . 1993 Oncogene 8: 203–207

  • Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G . 1996 J. Biol. Chem. 271: 29380–29385

  • Heuvel S, Harlow E . 1993 Science 262: 2050–2054

  • Hietanen S, Lain S, Krausz E, Blattner C, Lane DP . 2000 Proc. Natl. Acad. Sci. USA 97: 8501–8506

  • Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW . 2000 Science 287: 1824–1827

  • Juven-Gershon T, Oren M . 1999 Mol. Med. 5: 71–83

  • Kapoor M, Hamm R, Yan W, Taya Y, Lozano G . 2000 Oncogene 19: 358–364

  • Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B . 1993 Cancer Res. 53: 2231–2234

  • Li L, Ljungman M, Dixon JE . 2000 J. Biol. Chem. 275: 2410–2414

  • Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC . 1999 Oncogene 18: 583–592

  • Lu H, Taya Y, Ikeda M, Levine AJ . 1998 Proc. Natl. Acad. Sci. USA 95: 6399–6402

  • Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J . 2000 Oncogene 19: 232–240

  • McMasters KM, Montes de Oca Luna R, Pena JR, Lozano G . 1996 Oncogene 13: 1731–1736

  • Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP . 1997 Eur. J. Biochem. 243: 527–536

  • Meng RD, Shih H, Prabhu NS, George DL, El-Deiry WS . 1998 Clin. Cancer Res. 4: 251–259

  • Moll UM, Riou G, Levine AJ . 1992 Proc. Natl. Acad. Sci. USA 89: 7262–7266

  • Moll UM, LaQuaglia M, Benard J, Riou G . 1995 Proc. Natl. Acad. Sci. USA 92: 4407–4411

  • O'Grady A, Kay EW, McKenna DB, Bennett MA, Murphy GM, Leader MB . 1998 Hum. Pathol. 29: 559–564

  • Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B . 1992 Nature 358: 80–83

  • Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ . 1998 EMBO J. 17: 554–564

  • Sankrithi N, Eskin A . 1999 J. Neurochem. 72: 605–613

  • Schang LM, Rosenberg A, Schaffer PA . 1999 J. Virol. 73: 2161–2172

  • Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V . 1990 Mol. Cell Biol. 10: 6565–6577

  • Sherr CJ . 1998 Genes Dev. 12: 2984–2991

  • Shieh SY, Ahn J, Tamai K, Taya Y, Prives C . 2000 Genes Dev. 14: 289–300

  • Slingerland JM, Jenkins JR, Benchimol S . 1993 EMBO J. 12: 1029–1037

  • Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM . 1999 EMBO J. 18: 1660–1672

  • Tao W, Levine AJ . 1999 Proc. Natl. Acad. Sci. USA 96: 3077–3080

  • Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S . 1994 Eur. J. Biochem. 224: 771–786

  • Wang Y, Prives C . 1995 Nature 376: 88–91,

  • Wu L, Levine AJ . 1997 Mol. Med. 3: 441–451

  • Wu X, Bayle JH, Olson D, Levine AJ . 1993 Genes Dev. 7: 1126–1132

Download references

Acknowledgements

This work was supported by the H. Lee Moffitt Cancer Center and by grants from the National Institutes of Health and the American Cancer Society to J Chen.

Author information

Authors and Affiliations

  1. Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, 33612, Florida, FL, USA

    Wenge Lu, Lihong Chen, Yanhua Peng & Jiandong Chen

Authors
  1. Wenge Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lihong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanhua Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiandong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, W., Chen, L., Peng, Y. et al. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20, 3206–3216 (2001). https://doi.org/10.1038/sj.onc.1204412

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204412

Keywords

This article is cited by

Search

Advanced search

Quick links